SAN DIEGO--(BUSINESS WIRE)--
Retrophin, Inc. (NASDAQ:RTRX) today announced the addition of Tim
Coughlin, C.P.A. to the Company's Board of Directors as a fifth
independent director, effective March 31, 2015.
"We are pleased to welcome Tim to the Board of Directors," said Stephen
Aselage, Chief Executive Officer of Retrophin. "Tim's financial
oversight and expertise within the industry will provide invaluable
guidance to Retrophin as we continue moving into our next phase of
growth and generate significant value for our shareholders."
Mr. Coughlin has served as Chief Financial Officer of Neurocrine
Biosciences, a biopharmaceutical company focused on the discovery and
development of innovative, life-changing pharmaceuticals, since 2006.
Mr. Coughlin has experience in corporate accounting, finance, and
operations management of companies ranging in size from start-ups
through Fortune 500. Prior to Neurocrine, he served as Vice President of
Financial Services at CHI, a nationwide integrated healthcare delivery
system. From 1989 to 1999, Mr. Coughlin served as a Senior Manager in
the Health Sciences practice of Ernst & Young, and its predecessors.
Mr. Coughlin currently serves on the Board of Directors of Fate
Therapeutics, a clinical-stage biopharmaceutical company engaged in the
discovery and development of pharmacologic modulators of adult stem
cells to treat severe, life-threatening diseases. Mr. Coughlin holds a
Bachelor's in Accounting from Temple University and a Master's in
International Business from San Diego State University.
About Retrophin
Retrophin is a pharmaceutical company focused on the development,
acquisition and commercialization of drugs for the treatment of serious,
catastrophic or rare diseases for which there are currently no viable
options for patients. The Company's approved products include Chenodal®
and Thiola®, and its pipeline includes compounds for several
catastrophic diseases, including focal segmental glomerulosclerosis
(FSGS), pantothenate kinase-associated neurodegeneration (PKAN),
infantile spasms, nephrotic syndrome and others. For additional
information, please visit www.retrophin.com.
Retrophin, Inc.
Chris Cline, CFA, 646-564-3680
Manager,
Investor Relations
IR@retrophin.com
Source: Retrophin, Inc.
News Provided by Acquire Media